Interestingly, CRP has been found to reflect circulating sex hormone levels and hormone replacement therapy (24, 28–30), which we have previously linked to HF risk in the UK Biobank (31) and suggests the involvement of metabolic alterations in the pathway. This evidence concerns the gene PLXNA3 and hydrops fetalis.